Last edition
News about "Shanghai Ark Biopharmaceutical "
ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis
FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.
Shanghai Ark Biopharmaceutical | 12/02/2026 | By News Bureau
China Approves Azstarys for ADHD Treatment
ArkBio secures NMPA nod for once-daily ADHD treatment in China.
Shanghai Ark Biopharmaceutical | 06/01/2026 | By News Bureau | 140
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy